NOIN.BO
Latest Trade
609.50INRChange
11.45(+1.91%)Volume
4,128Today's Range
-
611.5052 Week Range
-
789.90As of on the Bombay Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 598.05 |
|---|---|
Open | 600.00 |
Volume | 4,128 |
3M AVG Volume | 0.12 |
Today's High | 611.50 |
Today's Low | 597.95 |
52 Week High | 789.90 |
52 Week Low | 558.00 |
Shares Out (MIL) | 24.69 |
Market Cap (MIL) | 15,010.77 |
Forward P/E | -- |
Dividend (Yield %) | 1.64 |
Novartis India June-Qtr Profit Drops
Novartis India March-qtr Profit Falls
Novartis India Dec-Qtr Profit Falls
Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods. The Company focuses on over three divisions, including pharmaceuticals, eye care and generic medicines. The Pharmaceuticals segment includes a portfolio of prescription medicines, which are provided to patients through healthcare professionals. Its Pharmaceutical business is focused on bone and pain, calcium portfolio, gynecology and neurosciences. The pharmaceuticals division is engaged in the development and commercialization in oncology, primary care and specialty medicines. The Generics segment comprises retail generics products. The business unit primarily focuses on the therapeutic segments, such as anti-tuberculosis (TB), anti-dysfunctional uterine bleeding (DUB (Gynecology)), antihistamines, antibiotics, anti-ulcerants, anti-diabetes and cardiovascular. The Company's geographical segments include India and Other Countries.
Industry
Biotechnology & Drugs
Contact Info
3Rd Floor, Royal Insurance, Bldg
14 J Tata Road
Churchgate
+91.22.24958400
https://www.novartis.in/Executive Leadership
Christopher Snook
Non-Executive Chairman of the Board
Sanjay Murdeshwar
Vice Chairman of the Board, Managing Director
Monaz Noble
Chief Financial Officer, Additional Whole Time Director
Trivikram Guda
Compliance Officer, Company Secretary
V. A. Kumar
Key Management Personnel
Price To Earnings (TTM) | 35.27 |
|---|---|
Price To Sales (TTM) | 3.25 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | 31.08 |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
* GETS REFUND OF 1.88 BILLION RUPEES ON ACCOUNT OF FAVOURABLE ORDER OF INCOME TAX APPELLATE TRIBUNAL FOR FY 1994-95
* DEC QUARTER PROFIT 187.4 MILLION RUPEES VERSUS PROFIT 130.3 MILLION RUPEES YEAR AGO
* Sept quarter profit 261.2 mlnrupees versus profit of 222.1 million rupees last year
* Says approved proposal for share buyback worth up to 2.31 billion rupees Source text: http://www.bseindia.com/xml-data/corpfiling/AttachLive/27db088d-e614-4349-ad93-69edfcc5e32f.pdf Further company coverage:
* Says to consider a proposal for buyback of company's equity shares Source text: http://bit.ly/2hhCOfg Further company coverage:
* June quarter profit 70.3 million rupees versus profit of 190.7 million rupees last year
* Novartis india ltd - dec quarter net profit 130.3 million rupees
* Sept quarter total income from operations 1.75 billion rupees
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.